A Phase 4 interventional study of Tranexamic Acid in Blood Loss, Surgical and Blood Loss Anemia, sponsored by Henry Ford Health System. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Henry Ford Health System · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.
Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one is the 30th largest by enrollment, is one of 4 that started in 2017, is one of 18 in phase 4, and was the 13th registered.
213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.
Browse Blood Loss, Surgical studies →9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 2–17
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 2–17
Assiut University · Sites in Egypt
Ages 18–65 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 12 · Phase 4 18
First in 2007; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is close to the median of 80 across 160 interventional studies indexed under Blood Loss, Surgical.
Median enrollment 98 across the 46 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 46 have an industry lead sponsor. The 10 most frequent:
Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.
Henry Ford Health System has 1 study filed under Blood Loss, Surgical — fewer than ten, so there is no comparison to draw.
3 of the studies testing Tranexamic Acid in Blood Loss, Surgical that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03553186Phase 3Hospital for Special Surgery, New YorkTranexamic Acid in Adult Spinal Deformity Surgery | 2027-03 |
| NCT07565753The University of Texas Health Science Center at San AntonioTEAPOT Study Multisite | 2027-09-30 |
| NCT06580509The University of Texas Health Science Center at San AntonioTranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion.
Spine surgery is associated with large amount of perioperative blood loss. Factors influencing blood loss include surgical technique, operative time, number of vertebral levels arthrodesed, and others. Significant blood loss is associated with complications such as hypotension, end organ damage, or coagulopathy. Blood transfusions can increase risks of infection, blood incompatibility, and allergic reactions. Due to the significant risks and complications associated with blood loss and allogenic transfusions, efforts to identify safe and effective ways of lowering blood loss during spine surgery are crucial. Many methods have been utilized to reduce allogenic blood transfusions, such as autologous blood predonation, antifibrinolytic drugs, acute normovolemic hemodilution, intraoperative blood salvage, and others. Furthermore, the administration of antifibrinolytics, such as tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA), has been shown to reduce bleeding in cardiac, gynecological, urologic and total joint replacement surgeries. There have been many published studies investigating various antifibrinolytic agents such as TXA, EACA, and aprotinin. While aprotinin was shown to increase mortality rate in patients following cardiac surgery, TXA and EACA have not been shown to cause any substantial morbidity or to increase rate of thromboembolic events. Although IV TXA has been shown to be effective in reducing blood loss and transfusions in patients undergoing spine surgery, no studies in the literature have investigated the efficacy of PO TXA in decreasing blood loss and transfusions. The investigators believe that PO TXA will be just as efficacious and more cost-effective in reducing blood loss and transfusion needs in patients undergoing lumbar spine surgery.
The ultimate goal is identifying the most cost-effective protocol to decrease blood loss and need for transfusion. If oral TXA is found to be as efficacious as IV TXA in reducing blood loss and need for transfusion, significant cost savings can be achieved for the patient and the health care system in general.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
Drug: Tranexamic Acid
The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
Drug: Tranexamic Acid
To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
Also known as: Lysteda
Post-operative Change in Hemoglobin Level Between the Two Groups
Time frame: Day of surgery up to 24 hours day after surgery
Post-operative Change of Blood Volume in Milliliters Between the Two Groups
The total blood volume change is calculated in milliliters
Time frame: 1 day after surgery until 7 days after surgery
Number of Participants Transfused Between the Two Groups
Time frame: 1 day after surgery until patient is discharged, up to 7 days
Number of Participants Experiencing a Thromboembolic Event Between the Two Groups
Time frame: 1 day after surgery until post operative visit 4 weeks after surgery
| Milestone | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| Started | 43 | 40 |
| Completed | 43 | 40 |
| Not completed | 0 | 0 |
| grams per deciliter | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| Post-operative Change in Hemoglobin Level Between the Two Groups | 3.36 (3 to 4) | 3.43 (3 to 4) |
The total blood volume change is calculated in milliliters
| milliliters (mL) | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| Post-operative Change of Blood Volume in Milliliters Between the Two Groups | 1235 (500 to 1420) | 1312 (480 to 1320) |
| Participants | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| Number of Participants Transfused Between the Two Groups | 21 | 10 |
| Participants | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| Number of Participants Experiencing a Thromboembolic Event Between the Two Groups | 2 | 2 |
Collected over From day of surgery until 4 week post-operative visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Tranexamic Acid | 0/43 (0%) | 0/43 (0%) | 2/43 (4.7%) |
| Oral Tranexamic Acid | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Event | Intravenous Tranexamic Acid | Oral Tranexamic Acid |
|---|---|---|
| thromboemolitic event (DVT/PE)Vascular disorders | 2/43 | 2/40 |
| Age, Categorical(Participants) | Intravenous Tranexamic Acid | Oral Tranexamic Acid | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 43 | 40 | 83 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Intravenous Tranexamic Acid | Oral Tranexamic Acid | Total |
|---|---|---|---|
| Female | 24 | 25 | 49 |
| Male | 19 | 15 | 34 |
| Race and Ethnicity Not Collected(Participants) | Intravenous Tranexamic Acid | Oral Tranexamic Acid | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Intravenous Tranexamic Acid | Oral Tranexamic Acid | Total |
|---|---|---|---|
| United States | 43 | 40 | 83 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jun 2018, 16 months.
Results were first posted in Nov 2026, 8 years 4 months after primary completion.
Of 24 non-industry phase 4 interventional studies under Blood Loss, Surgical, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 16 months is above that.
Counting every sponsor, half of 24 studies reached it within 12 months; a quarter within 8 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid